secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0000950170-25-069195
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dianthus Q1 net loss $29.5M; gMG trial enrollment complete, top-line Sep 2025
-----------------------------------------------------------------------------

- Net loss $29.5M ($0.82/sh) vs $13.7M ($0.54/sh) Q1 2024; cash $331.5M, runway into 2H'27.
- Phase 2 MaGic gMG trial enrolled 65 patients; top-line results expected September 2025.
- Phase 3 CAPTIVATE CIDP trial ongoing; interim responder analysis 2H'26.
- Phase 2 MoMeNtum MMN trial ongoing; top-line results 2H'26.
- Appointed John C. King as CCO and Sujay Kango to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000095017025069195/0000950170-25-069195-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000095017025069195/dnth-20250512.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-069195

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer